Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.37 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.35 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.35 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 2/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.34 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2249809 | 0.93 | SRC (0.41) | PKMMAPK8MAPK10MAPK14KDM4E | |
| SCHEMBL2248615 | 0.92 | FGFR1 (0.39) | PKMMAPK14FGFR1WEE1 | |
| SCHEMBL2248978 | 0.88 | POLR1A (0.38) | HPGDKDM4EALDH1A1HSD17B10MAP4K4 | |
| SCHEMBL2252397 | 0.86 | FGFR1 (0.37) | MAPK14FGFR1WEE1 | |
| SCHEMBL2245460 | 0.86 | FGFR1 (0.33) | MAPK14FGFR1WEE1 | |
| SCHEMBL2246694 | 0.84 | HSD17B10 (0.38) | PKMMAPK14HPGDKDM4EALDH1A1 | |
| SCHEMBL2249782 | 0.83 | FGFR1 (0.32) | PKMMAPK14FGFR1 | |
| SCHEMBL2247924 | 0.82 | SRC (0.42) | MAPK14FGFR1WEE1 | |
| SCHEMBL2247060 | 0.81 | HTR4 (0.38) | HPGDKDM4EALDH1A1HSD17B10FGFR1 | |
| SCHEMBL2248666 | 0.81 | SRC (0.40) | HPGDKDM4EALDH1A1HSD17B10MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | claimed |
| US-8518958-B2 | Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2013-08-27 | — | — | US | claimed |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Valo Health, LLC | 2011-08-18 | — | — | US | claimed |
| EP-2084159-A1 | PYRIDO Ý2, 3-D¨PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC Biotech Inc. (US) | 2009-08-05 | — | — | EP | claimed |
| WO-2008047307-A1 | PYRIDO [2, 3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | GPC BIOTECH INC. (US) | 2008-04-24 | — | — | WO | claimed |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | FORMA THERAPEUTICS, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| US-8518958-B2 | Pyrido [2,3-D] pyrimidines and their use as kinase inhibitors | FORMA THERAPEUTICS, INC. (US) | 2013-08-27 | — | — | US | disclosed |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | Valo Health, LLC | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163006-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PKM 461/4885MAPK8 142/4885MAPK10 307/4885 |
| US-20140163003-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PKM 461/4885MAPK8 142/4885MAPK10 307/4885 |
| US-20140163007-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PKM 461/4885MAPK8 142/4885MAPK10 307/4885 |
| US-20140163005-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PKM 461/4885MAPK8 142/4885MAPK10 307/4885 |
| US-20140163222-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PKM 461/4885MAPK8 142/4885MAPK10 307/4885 |
| US-20140163004-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PKM 461/4885MAPK8 142/4885MAPK10 307/4885 |
| US-20140163223-A1 | Pyrido-[2,3-D] Pyrimidines and Their Use as Kinase Inhibitors | DCK, PDXK, CDK2 | PKM 461/4885MAPK8 142/4885MAPK10 307/4885 |
| US-20110201594-A1 | PYRIDO [2,3-D] PYRIMIDINES AND THEIR USE AS KINASE INHIBITORS | DCK, PDXK, TK1 | PKM 485/4885MAPK8 157/4885MAPK10 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.